Drug Profile


Alternative Names: DSC 103; F6VD3; Flocalcitriol; Fulstan; Hexafluorocalcitriol; Hexafluorovitamin D3; Hornel; SM 8000; ST 630

Latest Information Update: 11 Jul 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Wisconsin-Madison
  • Developer Bertek Pharmaceuticals; Discovery Laboratories; Sumitomo Dainippon Pharma; Taisho Pharmaceutical
  • Class Calcium regulators; Dihydroxycholecalciferols
  • Mechanism of Action Calcitriol stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Hyperparathyroidism; Osteomalacia; Rickets
  • Discontinued Acne; Photodamage; Postmenopausal osteoporosis; Psoriasis

Most Recent Events

  • 19 Jun 2014 Dainippon Sumitomo Pharma is now called Sumitomo Dainippon Pharma
  • 07 Aug 2007 Discontinued - Phase-I for Acne in USA (Topical)
  • 07 Aug 2007 Discontinued - Phase-I for Photodamage in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top